{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:40:04Z","timestamp":1781703604651,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007604"],"award-info":[{"award-number":["T32HL007604"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11886-024-02100-y","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:05:14Z","timestamp":1721732714000},"page":"911-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?"],"prefix":"10.1007","volume":"26","author":[{"given":"Siddharth M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2100_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","volume":"20","author":"AD Elliott","year":"2023","unstructured":"Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20:404\u201317. https:\/\/doi.org\/10.1038\/s41569-022-00820-8.","journal-title":"Nat Rev Cardiol"},{"key":"2100_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138. https:\/\/doi.org\/10.1161\/01.STR.22.8.983.","journal-title":"Stroke"},{"key":"2100_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to prevent stroke in patients who have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146:857\u201367. https:\/\/doi.org\/10.7326\/0003-4819-146-12-200706190-00007.","journal-title":"Ann Intern Med"},{"key":"2100_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2024;149:e1\u2013156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"key":"2100_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"key":"2100_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0.","journal-title":"Lancet"},{"key":"2100_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","volume":"1","author":"JC Hsu","year":"2016","unstructured":"Hsu JC, Maddox TM, Kennedy KF, Katz DF, Marzec LN, Lubitz SA, et al. Oral anticoagulant therapy prescription in patients with Atrial Fibrillation across the Spectrum of Stroke Risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1:55\u201362. https:\/\/doi.org\/10.1001\/jamacardio.2015.0374.","journal-title":"JAMA Cardiol"},{"key":"2100_CR8","doi-asserted-by":"publisher","first-page":"e2242964","DOI":"10.1001\/jamanetworkopen.2022.42964","volume":"5","author":"D Ko","year":"2022","unstructured":"Ko D, Lin KJ, Bessette LG, Lee SB, Walkey AJ, Cheng S, et al. Trends in Use of oral anticoagulants in older adults with newly diagnosed Atrial Fibrillation, 2010\u20132020. JAMA Netw Open. 2022;5:e2242964. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.42964.","journal-title":"JAMA Netw Open"},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"\u25cf\u25cfHsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. Factor XI inhibition to uncouple thrombosis from Hemostasis. J Am Coll Cardiol. 2021;78:625\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.010. A comprehensive review of the factor XI hypothesis.","journal-title":"J Am Coll Cardiol"},{"key":"2100_CR10","doi-asserted-by":"publisher","unstructured":"\u25cf\u25cfHarrington J, Piccini JP, Alexander JH, Granger CB, Patel MR. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;81:771\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.057. A comprehensive review of the factor XI hypothesis and current factor XI pathway inhibitor programs across clinical indications..","DOI":"10.1016\/j.jacc.2022.11.057"},{"key":"2100_CR11","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","volume":"21","author":"JC Fredenburgh","year":"2023","unstructured":"Fredenburgh JC, Weitz JI. News at XI: moving beyond factor xa inhibitors. J Thromb Haemost. 2023;21:1692\u2013702. https:\/\/doi.org\/10.1016\/j.jtha.2023.04.021.","journal-title":"J Thromb Haemost"},{"key":"2100_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ehjcvp\/pvae002","volume":"10","author":"G Occhipinti","year":"2024","unstructured":"Occhipinti G, Laudani C, Spagnolo M, Finocchiaro S, Mazzone PM, Faro DC, et al. Pharmacological and clinical appraisal of factor XI inhibitor drugs. Eur Heart J - Cardiovasc Pharmacother. 2024;10:245\u201358. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae002.","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"key":"2100_CR13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129:1210\u20135. https:\/\/doi.org\/10.1182\/blood-2016-09-742262.","journal-title":"Blood"},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","volume":"10","author":"F Peyvandi","year":"2012","unstructured":"Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of rare bleeding disorders. J Thromb Haemost. 2012;10:615\u201321. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04653.x.","journal-title":"J Thromb Haemost"},{"key":"2100_CR15","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","volume":"50","author":"B Georgi","year":"2019","unstructured":"Georgi B, Mielke J, Chaffin M, Khera AV, Gelis L, Mundl H, et al. Leveraging Human Genetics to Estimate Clinical Risk reductions Achievable by inhibiting factor XI. Stroke. 2019;50:3004\u201312. https:\/\/doi.org\/10.1161\/STROKEAHA.119.026545.","journal-title":"Stroke"},{"key":"2100_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1056\/NEJM199107183250303","volume":"325","author":"R Asakai","year":"1991","unstructured":"Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI Deficiency in Ashkenazi jews in Israel. N Engl J Med. 1991;325:153\u20138. https:\/\/doi.org\/10.1056\/NEJM199107183250303.","journal-title":"N Engl J Med"},{"key":"2100_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","volume":"3","author":"X Wang","year":"2005","unstructured":"Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu M, Smith PL, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3:695\u2013702. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01236.x.","journal-title":"J Thromb Haemost"},{"key":"2100_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","volume":"113","author":"EI Tucker","year":"2009","unstructured":"Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJT, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113:936\u201344. https:\/\/doi.org\/10.1182\/blood-2008-06-163675.","journal-title":"Blood"},{"key":"2100_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","volume":"33","author":"JR Crosby","year":"2013","unstructured":"Crosby JR, Marzec U, Revenko AS, Zhao C, Gao D, Matafonov A, et al. Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates. Arterioscler Thromb Vasc Biol. 2013;33:1670\u20138. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301282.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2100_CR20","doi-asserted-by":"publisher","unstructured":"\u25cf\u25cfPiccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet. 2022;399:1383\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1. A phase 2 randomized trial of asundexian, a small molecule oral factor XIa inhibitor, compared with apixaban, in 755 patients with atrial fibrillation followed for 12 weeks.","DOI":"10.1016\/S0140-6736"},{"key":"2100_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400:997\u20131007. https:\/\/doi.org\/10.1016\/S0140-6736(22)01588-4.","journal-title":"Lancet"},{"key":"2100_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","volume":"146","author":"SV Rao","year":"2022","unstructured":"Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, Multicenter A, et al. Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse Cardiovascular outcomes after Acute myocardial infarction. Circulation. 2022;146:1196\u2013206. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061612.","journal-title":"Circulation"},{"key":"2100_CR23","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. Milvexian for the Prevention of venous thromboembolism. N Engl J Med. 2021;385:2161\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2113194.","journal-title":"N Engl J Med"},{"key":"2100_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. Effect of Osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT Randomized Clinical Trial. JAMA. 2020;323:130\u20139. https:\/\/doi.org\/10.1001\/jama.2019.20687.","journal-title":"JAMA"},{"key":"2100_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi AB, Segers A, Salter J, Bloomfield D, B\u00fcller HR, et al. Abelacimab for Prevention of venous thromboembolism. N Engl J Med. 2021;385:609\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2105872.","journal-title":"N Engl J Med"},{"key":"2100_CR26","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","volume":"138","author":"CU Lorentz","year":"2021","unstructured":"Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138:2173\u201384. https:\/\/doi.org\/10.1182\/blood.2021011725.","journal-title":"Blood"},{"key":"2100_CR27","doi-asserted-by":"publisher","unstructured":"\u25cf\u25cfRuff CT, AZALEA-TIMI 71 Steering Committee. Abelacimab, a novel factor XI\/XIa inhibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the AZALEA-TIMI 71 randomized trial. Circulation,. 2024;148:e282\u2013317. https:\/\/doi.org\/10.1161\/CIR.0000000000001200. A phase 2 randomized trial of abelacimab, an injectable monoclonal antibody inhibitor of factor XI\/XIa, compared with rivaroxaban in 1,287 patients with atrial fibrillation followed for a median of 1.8 years.","DOI":"10.1161\/CIR.0000000000001200"},{"key":"2100_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2022","unstructured":"Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ, et al. Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep. 2022;7:200\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.011.","journal-title":"Kidney Int Rep"},{"key":"2100_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI. Factor XI antisense oligonucleotide for Prevention of venous thrombosis. N Engl J Med. 2015;372:232\u201340.","journal-title":"N Engl J Med"},{"key":"2100_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.02.024","author":"WC Winkelmayer","year":"2024","unstructured":"Winkelmayer WC, Lensing AWA, Thadhani RI, Mahaffey KW, Walsh M, Pap \u00c1F, et al. A phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024. https:\/\/doi.org\/10.1016\/j.kint.2024.02.024.","journal-title":"Kidney Int"},{"key":"2100_CR31","doi-asserted-by":"publisher","first-page":"ehad6552843","DOI":"10.1093\/eurheartj\/ehad655.2843","volume":"44","author":"L Gan","year":"2023","unstructured":"Gan L, Li C, Sun Y, Wikstrom J, Guo Z, Yu H, et al. Inhibition of factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration. Eur Heart J. 2023;44:ehad6552843. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.2843.","journal-title":"Eur Heart J"},{"key":"2100_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23:46\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(23)00403-9.","journal-title":"Lancet Neurol"},{"key":"2100_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","volume":"30","author":"JI Weitz","year":"2024","unstructured":"Weitz JI, Tank\u00f3 LB, Floege J, Fox KAA, Bhatt DL, Thadhani R, et al. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med. 2024;30:435\u201342. https:\/\/doi.org\/10.1038\/s41591-023-02794-7.","journal-title":"Nat Med"},{"key":"2100_CR34","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/jth.15439","volume":"19","author":"D Thomas","year":"2021","unstructured":"Thomas D, Kanefendt F, Schwers S, Unger S, Yassen A, Boxnick S. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost. 2021;19:2407\u201316. https:\/\/doi.org\/10.1111\/jth.15439.","journal-title":"J Thromb Haemost"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02100-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:53:57Z","timestamp":1725623637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02100-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02100-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"10 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<b>Human and Animal Rights and Informed Consent<\/b>.No animal or human subjects by the authors were used in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Ruff reports grants from Anthos, grants from Janssen, personal fees from Bayer, outside the submitted work; and Dr. Ruff reports research grants through Brigham and Women\u2019s Hospital from Anthos, AstraZeneca, Daiichi Sankyo, Janssen, and Novartis and has received honoraria for scientific advisory boards and consulting from Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, and Pfizer. Drs. Ruff and Patel are members of the TIMI Study Group which as received institutional research grant support through Brigham and Women\u2019s Abbott, Abiomed, Inc., Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Saghmos Therapeutics, Inc., Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited, The Medicines Company, Verve Therapeutics, Inc., and Zora Biosciences. Dr. Patel reports consulting fees from Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}